Get the Stockscreener App
1.05
3.67%
-0.04
Cue Biopharma Inc stock is traded at $1.05, with a volume of 163.76K.
It is down -3.67% in the last 24 hours and down -37.50% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
See More
Previous Close:
$1.09
Open:
$1.09
24h Volume:
163.76K
Relative Volume:
0.23
Market Cap:
$65.93M
Revenue:
$3.82M
Net Income/Loss:
$-51.89M
P/E Ratio:
-0.8268
EPS:
-1.27
Net Cash Flow:
$-39.52M
1W Performance:
-30.00%
1M Performance:
-37.50%
6M Performance:
-44.30%
1Y Performance:
-55.88%
1-Day Range:
$1.02
$1.09
1-Week Range:
$1.02
$1.5599
52-Week Range:
$0.45
$3.2491
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CUE | 1.045 | 65.93M | 3.82M | -51.89M | -39.52M | -1.27 |
| VRTX | 447.61 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.87 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN
Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK
Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartzy
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma's Cancer Drug Shows 91% Survival Rate in Phase 1 Trial, Revenue Up 57% | CUE Stock News - StockTitan
Cue Biopharma Announces Strategic Organizational Transition - GlobeNewswire
Cue Biopharma Strengthens Leadership: J&J Veteran with 15+ Drug Approvals Joins as CDO | CUE Stock News - StockTitan
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus reshapes outlook - Investing.com Australia
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - The Manila Times
Cue Biopharma to Present Latest Clinical Trial Data at Stifel Healthcare Conference | CUE Stock News - StockTitan
Cue Biopharma Presents Positive Updated Data from its Phase - GlobeNewswire
Cue Biopharma Cancer Drug Trial Soars: 91% Survival Rate, Shatters Expectations | CUE Stock News - StockTitan
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Cue Biopharma authorizes more shares By Investing.com - Investing.com Australia
Cue Biopharma authorizes more shares - Investing.com India
There is no doubt that Cue Biopharma Inc (CUE) ticks all the boxes. - SETE News
Market Watch: Cue Biopharma Inc (CUE)’s Noteworthy Drop, Closing at 1.23 - The Dwinnex
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% - Yahoo Finance
Technical analysis of Cue Biopharma Inc (CUE) stock chart patterns - US Post News
Cue Biopharma stock rallies nearly 40% on upcoming presentations - MSN
Cue Biopharma amends loan agreement, easing cash requirements - Investing.com India
Cue Biopharma amends loan agreement, easing cash requirements By Investing.com - Investing.com UK
Cue Biopharma Announces Upcoming Scientific Presentations - GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan
Quarterly Snapshot: Quick and Current Ratios for Cue Biopharma Inc (CUE) - The Dwinnex
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Views of Wall Street’s Leading Experts on Cue Biopharma Inc - SETE News
What to expect from Cue Biopharma Inc’s (CUE) current quarter earnings? - US Post News
Cue Biopharma Inc (CUE) Stock: A Year of Highs and Lows - The InvestChronicle
Form 424B5 Cue Biopharma, Inc. - StreetInsider.com
SEC Form 424B5 filed by Cue Biopharma Inc. - Quantisnow
Wall Street SWOT: Cue Biopharma stock pivots to autoimmune focus amid restructuring - Investing.com India
Cue biopharma announces proposed public offering - MSN
Cue Biopharma prices $12M stock offering - MSN
Cue Biopharma Prices of $12.0 Million Public Offering - citybiz
Cue Biopharma Announces Pricing of $12.0 Million Public Offering - StockTitan
Cue Biopharma Announces Proposed Public Offering - The Bakersfield Californian
Cue Biopharma launches public stock offering By Investing.com - Investing.com Australia
Cue Biopharma launches public stock offering - Investing.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):